Market revenue in 2023 | USD 1,428.1 million |
Market revenue in 2030 | USD 2,521.7 million |
Growth rate | 8.5% (CAGR from 2023 to 2030) |
Largest segment | Regulatory writing & publishing |
Fastest growing segment | Legal Representation |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services |
Key market players worldwide | Genpact Ltd, Icon PLC, Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Drug Development, Cencora Inc, Pharmexon, QVigilance, Voisin Consulting Life Sciences, Accell, Criterium Inc., Freyr Solutions, PharmaLex, NDA Regulatory Service GmbH, BlueReg Group, Cambridge Regulatory Services |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical regulatory affairs market will help companies and investors design strategic landscapes.
Regulatory writing & publishing was the largest segment with a revenue share of 31.5% in 2023. Horizon Databook has segmented the Asia Pacific biopharmaceutical regulatory affairs market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, other services covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to be the largest pharmaceutical regulatory affairs market due to the improved regulatory landscape, cost savings, growing number of clinical trials conducted in the region, and increasing number of biopharmaceutical companies in the region.
Furthermore, the availability of a skilled workforce at a lower cost than in the U.S. is another factor expected to propel growth. Similarly, the expansion of established biopharmaceutical companies may increase the demand for regulatory service providers.
This is owing to the heterogeneous and complex regulatory environment, fueling the growth of the pharmaceutical regulatory affairs market. Cost efficiency is a major factor for outsourcing regulatory affairs services, as biopharmaceutical companies face tremendous pressure to reduce the cost of R&D.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific biopharmaceutical regulatory affairs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific biopharmaceutical regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account